Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Mpox Vaccine

MVA-BN Mpox 疫苗剂量减少策略免疫原性评估试验

• 批准号: 10889287
• 负责人: THERESA ENGEL
• 金额: $ 664.52万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-19 至 2024-09-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10889287
• 关键词: Adult; Age Years; Clinical Trials; Dose; Evaluation; Modified Vaccinia Virus Ankara; Monkeypox; Multi-Institutional Clinical Trial; Phase; Randomized; Regimen; Vaccines; Vaccinia; immunogenicity; open label; subcutaneous

This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the standard subcutaneous (SC) regimen in healthy, vaccinia-naïve adults 18 to 50 years of age.

该研究是一项2期随机、开放标签、非安慰剂对照、多地点临床试验，将在18至50岁的vaccinia-naïve健康成年人中评估两种改良安卡拉-巴伐利亚北欧牛痘（MVA-BN）疫苗的皮内（ID）方案与标准皮下（SC）方案的比较。